Drugs / AD-2132
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04755985 | Mar → May 2021 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-2132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04755985 ↗ |
| Route | Oral | “After oral administration” NCT04755985 ↗ |